Loading...
•
Dec 31, 2021
Edgewise Therapeutics Q4 2021 Earnings Report
Reported financial results for the fourth quarter and full year of 2021 and recent business highlights.
Key Takeaways
Edgewise Therapeutics reported positive topline results from the EDG-5506 Phase 1b clinical trial in adults with Becker muscular dystrophy (BMD). Phase 2 trials in BMD and Duchenne muscular dystrophy (DMD) are planned to start in 2022. Cash, cash equivalents and marketable securities were $281 million as of December 31, 2021.
Announced positive topline results from the EDG-5506 Phase 1b clinical trial in adults with Becker muscular dystrophy (BMD).
Phase 2 trials in BMD and Duchenne muscular dystrophy (DMD) planned to start in 2022.
Initiated treatment in the ARCH open label study evaluating EDG-5506 in adult males with BMD.
Cash, cash equivalents and marketable securities were $281 million as of December 31, 2021.
Edgewise Therapeutics
Edgewise Therapeutics
Forward Guidance
The Company anticipates initiating Phase 2 trials in individuals with BMD in the first half of 2022 and DMD in the second half of 2022. The Company anticipates interim data from the ARCH trial in the first half of 2022.
Positive Outlook
- Initiating Phase 2 trials in individuals with BMD in the first half of 2022
- Initiating Phase 2 trials in individuals with DMD in the second half of 2022
- Advancing the EDG-002 program, focused on identifying cardiac muscle modulators
- Advancing EDG-5440, a next generation myosin ATPase modulator designed to target skeletal muscle
- Anticipates interim data from the ARCH trial in the first half of 2022